BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30626019)

  • 1. Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy.
    Meany HJ
    Children (Basel); 2019 Jan; 6(1):. PubMed ID: 30626019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
    Irwin MS; Naranjo A; Zhang FF; Cohn SL; London WB; Gastier-Foster JM; Ramirez NC; Pfau R; Reshmi S; Wagner E; Nuchtern J; Asgharzadeh S; Shimada H; Maris JM; Bagatell R; Park JR; Hogarty MD
    J Clin Oncol; 2021 Oct; 39(29):3229-3241. PubMed ID: 34319759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroblastoma: clinical and biological approach to risk stratification and treatment.
    Tolbert VP; Matthay KK
    Cell Tissue Res; 2018 May; 372(2):195-209. PubMed ID: 29572647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without
    Wieczorek A; Szewczyk K; Klekawka T; Stefanowicz J; Ussowicz M; Drabik G; Pawinska-Wasikowska K; Balwierz W
    Front Oncol; 2023; 13():1134772. PubMed ID: 36865795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.
    Tumer S; Altungoz O; Bagci O; Olgun HN
    Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
    Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
    J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
    Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
    J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Neuroblastoma: ICMR Consensus Document.
    Bansal D; Totadri S; Chinnaswamy G; Agarwala S; Vora T; Arora B; Prasad M; Kapoor G; Radhakrishnan V; Laskar S; Kaur T; Rath GK; Bakhshi S
    Indian J Pediatr; 2017 Jun; 84(6):446-455. PubMed ID: 28367616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-based management: current concepts of treating malignant solid tumors of childhood.
    Grosfeld JL
    J Am Coll Surg; 1999 Oct; 189(4):407-25. PubMed ID: 10509467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
    Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
    J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.
    Look AT; Hayes FA; Shuster JJ; Douglass EC; Castleberry RP; Bowman LC; Smith EI; Brodeur GM
    J Clin Oncol; 1991 Apr; 9(4):581-91. PubMed ID: 2066755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
    Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
    Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of Segmental Chromosomal Aberrations in Patients with Neuroblastoma: First Report in Korean Population.
    Lim H; Son MH; Hyun JK; Cho HW; Ju HY; Lee JW; Yoo KH; Sung KW; Koo HH
    J Korean Med Sci; 2020 Apr; 35(14):e82. PubMed ID: 32281311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.
    Ahmed AA; Zhang L; Reddivalla N; Hetherington M
    Pediatr Hematol Oncol; 2017 Apr; 34(3):165-185. PubMed ID: 28662353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.